At Pulmobiotics, we engineer bacteria for the treatment of respiratory diseases. Here, we outline how we designed MycoChassis — an attenuated bacterium strain obtained by genome engineering of Mycoplasma pneumoniae (a human lung pathogen) — and discuss the challenges on the road to its clinical translation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fernández-Barat, L., López-Aladid, R. & Torres, A. Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome. EBioMedicine 60, 102995 (2020).
Rouzé, A. et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 47, 188–198 (2021).
Piñero-Lambea, C. et al. SURE editing: combining oligo-recombineering and programmable insertion/deletion of selection markers to efficiently edit the Mycoplasma pneumoniae genome. Nucleic Acids Res. 50, e127–e127 (2022).
Garrido, V. et al. Engineering a genome‐reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo. Mol. Syst. Biol. 17, (2021).
Mazzolini, R. et al. Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01584-9 (2023).
Montero-Blay, A. et al. Bacterial expression of a designed single-chain IL-10 prevents severe lung inflammation. Mol. Syst. Biol. 19, e11037 (2023).
Acknowledgements
I would like to acknowledge Pulmobiotics’ scientific team and the group of Design of Biological Systems (CRG) for the collaborative efforts that made possible the development of the proof-of-concept, especially L. Serrano, Principal Investigator of the group, co-founder of Pulmobiotics and CRG director.I would also like to thank the Technology and Business Development Office (TBDO; CRG), especially S. Tortola, A. Sanchez and C. Santos (now CEO of Pulmobiotics) for their support in the creation of Pulmobiotics. Special thanks to our investor Invivo Capital for their financial backing and strategic and business development support. Pulmobiotics is financed by Invivo Capital, by a project funded by CDTI with the collaboration of the Ministry of Science and Innovation and co-financed by the European Union Next Generation EU with the file number SNEO 20211019, by project CPP2021-008552 funded by MCIN/AEI /10.13039/501100011033 and by the European Union NextGenerationEU/ PRTR and by the European Union’s EIC Transition program, under Grant Agreement N° 101098475.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.L-S. is currently working in Pulmobiotics as Chief Scientific Officer (CSO) where she is co-author of patents and co-founder of the company.
Rights and permissions
About this article
Cite this article
Lluch-Senar, M. From science to business: translating live biotherapeutic products to the clinic. Nat Rev Bioeng 1, 462–463 (2023). https://doi.org/10.1038/s44222-023-00078-w
Published:
Issue date:
DOI: https://doi.org/10.1038/s44222-023-00078-w
This article is cited by
-
Exploiting bacteria for cancer immunotherapy
Nature Reviews Clinical Oncology (2024)
